PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH
Darolutamide plus ADT approved in EU for mHSPC
Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC
Experts urge FDA to remove black box warning on low-dose vaginal estrogen